Study of Phala Ghrit on Beejotsarga and its efficacy on Infertility due to Ovarian factor

Not yet recruiting

• Conditions: Female infertility associated withanovulation,

• Registration Number: CTRI/2023/05/053262
• Lead Sponsor: MOHAN YENDE

Brief Summary

Failure to ovulate is the major problem in India approximately 30% - 40% cases of female infertility. The Beeja is the core stone of the female reproductive process and absence of this factor Garbha cannot occur in spite of the proper Ritu, Kshetra and Ambu. Vagbhat stated the effect of Phalaghrita on Vandhyatva(infertility), so with an objective to study the effect of Phalaghruta in comparison with clomiphene citrate study will be carried out.  Materials and methods-This Single blind(participant) randomized control clinical involves two groups with 30 subjects each. Group A (Study Group)will be treated with administration of Phala Ghritain the dose of 10 ml B.D. orally with Anupana of cow milk 100 ml. Group B(Control Group)will be treated with administration of Tab. Clomiphene citrate50 mg O.D. orally for 5 days from day 3 to 7 of Menstrual cycle.

Expected outcome - Primary outcome of study will be development of follicle and Beejotsarga (ovulation) and Secondary outcome will be conception. Conclusion- Effect of drug Phala Ghrita will be stated as per observed result.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-05-29
• Study Start: 2023-06-19

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• Married females unable to conceive from 1 year of active married life 2.
• Irregular or scanty menses due to anovulatory cycle 4.
• Anovulatory cycle 5.
• Unruptured ovarian follicle.

Exclusion Criteria

• Unmarried and non-fertile age group patients 2.
• Infertility other than ovarian causes e.g. cervical, uterine causes.
• Cervical tumor, polyp, Ca cervix, Uterine fibroid 4.
• Congenital anomalies in female genital tract 5.
• Tubercular endometritis, Malignant and cytotoxic patients 6.
• HIV/VDRL/HbsAg positive 7.
• Non-Cooperative and patients.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Beejotsarga (Ovulation)	Cycle 1TVS from day 10 | Cycle 2 TVS from day 10 | Cycle 3TVS from day 10

Secondary Outcome Measures

Name	Time	Method
Conception	after 28 day of cycle

Trial Locations

Locations (2)

Jawaharlal Nehru Medical College , Sawangi; 🇮🇳 Wardha, MAHARASHTRA, India

Mahatma Gandhi Ayurveda College and Research Hospital; 🇮🇳 Wardha, MAHARASHTRA, India

Jawaharlal Nehru Medical College , Sawangi

🇮🇳Wardha, MAHARASHTRA, India

Dr Mohan Yende

Principal investigator

9970137300

yrmohan1@gmail.com